About Us

About Us

Founded in 2021, RinuaGene is dedicated to developing innovative RNA therapeutics and vaccines to address critical health challenges around the world.

With a strong foundation in scientific expertise, pharmaceutical industry experience, and managerial excellence, RinuaGene is efficiently advancing its FIC/BIC product pipeline and strengthening its cutting-edge technological platform.

Driven by innovation, RinuaGene is committed to establishing a world-class platform for RNA-based drugs and vaccines. Our goal is to deliver high-quality, transformative solutions that improve human health and contribute to a healthier future worldwide.

0 Patents Granted
0% Team for R&D
0% Advanced Degrees
Development
2021

2021

•  RinuaGene founded in Suzhou

•  2,800 ㎡ R&D center established with cGMP pilot plant

•  1st tox batch produced

2022

2022

•  RG001 IND application submitted, NIFDC test initiated

2023

2023

•  RG002-01 IND granted by US FDA, the 1st IND of mRNA immunotherapy for HPV-related cervical pre-cancer worldwide


2024

2024

•  Multiple patents granted for LNP delivery systems, within a library >10K lipids

•  RG002-01 IND granted by China NMPA

2025

2025

•  RG002-01 Phase I trial initiated in China

•  RG002-01 Phase I/IIa recruitment completed, excellent safety at all dose levels, 100% effectiveness demonstrated at the lowest dose


2026

2026

•  RG004 IND granted by US FDA, an RSV vaccine with novel multi-antigen design

•  RG002-01 Phase IIb recruitment started

•  200+ patents filed and 20+ granted

2021
2022
2023
2024
2025
2026